EUnetHTA 21 shares draft on medicinal JCA timelines in D5.4 deliverable

By HEOR Staff Writer

July 4, 2023

The objective is to produce Joint Clinical Assessments (JCA) for medicinal products and medical devices in order to improve quality, consistency, and national adoption of the JCA. The production process will be standardized. During the production, the methodological convergence paths defined in EUnetHTA JA3 will be tested, including the PICO concept paper and the GRADE framework paper. Additionally, the new methodological guidelines developed by EUnetHTA 21, as well as revised templates and guidelines, will be tested to address challenges identified in EUnetHTA JA3.

 

Read the draft document here: on the link below

Join the discussion on July 13th, 2023. Register now via Eventbrite at https://www.eventbrite.co.uk/e/eunethta-21-htd-meeting-tickets-647889433737?aff=oddtdtcreator 

Reference url

Recent Posts

large language models
Large Language Models in Evidence-Based Medicine

By João L. Carapinha

July 3, 2026

Large language models deliver rapid synthesis of medical literature, but according to research on fast information and slow evidence, they cannot independently generate validated evidence for clinical decisions. These tools sit at a...
pharmaceutical manufacturing affordability
Pharmaceutical Manufacturing Affordability as a Key to South Africa’s Local Production Goals

By João L. Carapinha

July 3, 2026

Pharmaceutical manufacturing affordability remains the decisive factor in South Africa’s efforts to build domestic capacity for essential medicines and vaccines. Government, industry and research leaders who met at the TIPS Development Dialogue on 17 June made clear that economic barriers to acce...
Shingles vaccine affordability
Shingles Vaccine Affordability and Its Impact on Public Health in South Africa

By João L. Carapinha

July 2, 2026

Shingles vaccine affordability remains a pressing concern as the recombinant zoster vaccine launches in South Africa. This vaccine delivers substantially higher efficacy and longer protection against herpes zoster and post-herpetic neuralgia than the live attenuated version withdrawn in 2024, yet...